Abstract: Embodiments of the application are directed toward a liquid topical sinus therapy for a patient, comprising a medicated formulation including at least one medication, and a device for delivering the medicated formulation to the patient's nostrils, nasal passages, or sinuses. The medicated formulation may include drugs selected from the group consisting of corticosteroids, antibiotics, antifungals, antihistamines as well as herbal and alternative medications. Dosage forms include powders, tablets and gels which facilitate clinical testing and enable patient compliance.
Abstract: Embodiments of the application involve a formulation of Fluticasone Propionate in the form of a suspension, gel or dry powder comprising Fluticasone Propionate, Fluticasone Furoate, Micronized Fluticasone Propionate or Micronized Fluticasone Furoate or other corticosteroids. Additional pharmaceutical components of the formulation may allow for the adherence and duration of the active ingredient to the inflamed esophageal tissues. The resulting medication formulation is then targeted with a drug delivery device and applied directly to the oropharynx bypassing the oral cavity altogether. The medication then flows down the back of the throat to the esophagus. By passing the oral cavity prevents the corticosteroid drug from being absorbed into the bloodstream through oral cavity tissues, helping to prevent harmful side effects. Additional side effects are avoided by using the medication Fluticasone, which exhibits exceptionally low gastrointestinal absorption.
Abstract: A medication or combination of medications for the treatment of a disease involving the sinuses is incorporated into a sterile medical gel. The viscosity of the gel or the adhesion of the gel to the patient's sinus cavity allows the gel to be maintained in the cavity for a sufficient length of time for treatment of the affected area, thereby reducing the amount of wasted medication that would otherwise result from other topical methods. In one embodiment, the medicated gel comprises a sterile viscous gel having a viscosity sufficient to be maintained within a paranasal sinus cavity after insertion, and a medication dispersed in the sterile viscous gel.
Abstract: A medication or combination of medications for the treatment of a disease involving the sinuses is incorporated into a sterile medical gel. The viscosity of the gel or the adhesion of the gel to the patient's sinus cavity allows the gel to be maintained in the cavity for a sufficient length of time for treatment of the affected area. This reduces the amount of wasted medication that would otherwise result from other topical methods.
Type:
Grant
Filed:
April 27, 2011
Date of Patent:
December 23, 2014
Assignee:
Topical Sinus Therapeutics, Inc.
Inventors:
Russell N. Reitz, Robert Scott Osbakken
Abstract: The present invention is directed to the treatment of infections and the associated symptoms of sinusitis, rhinitis and related neurological disorders of the cranial cavity and facial tissue. More specifically, the present invention is directed to aerosols that are used to treat infections and the associated symptoms of sinusitis, rhinitis and related neurological disorders of the cranial cavity and facial tissue, compositions from which the aerosols are generated and methods of generating the aerosols. In an aerosol aspect of the present invention, an aerosol for delivery to the sinus cavity of a patient is provided. The aerosol includes at least: a) one or more compounds selected from antibiotics, antifungals, leukotriene antagonists, anti-TNF compounds, antihistamines, steroidal antiinflammatories, mucolytics, estrogen, progesterone and related hormones; and, b) water The compounds are present in the water at a concentration ranging from 0.
Type:
Grant
Filed:
December 15, 2006
Date of Patent:
December 25, 2012
Assignee:
Topical Sinus Therapeutics, Inc.
Inventors:
Robert Scott Osbakken, Russell N. Reitz, John C. Tarrant